article thumbnail

Applied Virtual Reality in Healthcare: A comprehensive book on medical XR

pharmaphorum

Our book Applied Virtual Reality in Healthcare provides an overview of innovative approaches, best practices, and coherent solutions to common concerns. ” Additionally, pharma can use VR for monitoring brain health during treatments, such as chemotherapy. VR can be a useful venue for them.” About the interviewee.

article thumbnail

Opinion: What the public might learn from Kate Middleton, the latest ‘famous patient’

STAT

By the time I wrote my book , “When Illness Goes Public: Celebrity Patients and How We Look at Medicine” in 2006, there were hundreds of stories of famous patients I could have told.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy

pharmaphorum

The new approval is for use in patients with BRCA-mutated, HER2-negative early-stage breast cancer who have already been treated with chemotherapy – either before or after surgery – and are at high risk of the disease coming back. billion in sales for AZ last year, a rise of around 25%, while Merck booked just under $1 billion from the drug.

FDA 140
article thumbnail

BMS pays $650m upfront for Eisai’s first ADC candidate for cancer

pharmaphorum

Folate is a tried and tested target in cancer therapy, with chemotherapy drugs like methotrexate and pemetrexed working inside cancer cells to disrupt the pathway. Another rival is Sutro Biopharma, whose STRO-002 ADC candidate – partnered with Merck KGaA – has just started phase 1 testing.

article thumbnail

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

pharmaphorum

Giving Lynparza (olaparib) to women with BRCA-positive, HER2-negative breast cancer straight after chemotherapy and surgery to remove the tumour reduced the risk of recurrence, secondary cancers or death by 42% compared to placebo after 2.5 billion in sales for AZ last year, with Merck booking $725 million in alliance revenues.

article thumbnail

AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1

pharmaphorum

AZ and partner Merck & Co have filed Lynparza (olaparib) for use in BRCA-mutated, HER2-negative early breast cancer in patients who have already been treated with chemotherapy either before or after surgery and are at high risk of the disease coming back. billion in sales for AZ last year, while Merck booked $725 million from the drug.

FDA 111
article thumbnail

Takeda’s Iclusig bests imatinib in first-line leukaemia trial

pharmaphorum

The PhALLCON trial compared Iclusig (ponatinib) to imatinib – sold by Novartis as Glivec/Gleevec, but also available as a generic – on top of a reduced-intensity chemotherapy regimen in 230 patients with this type of leukaemia. Takeda booked 23.2